Akebia (AKBA) Therapeutics announced that it has commenced an underwritten public offering. All shares are being offered by Akebia. Leerink Partners and Piper Sandler & Co. are acting as joint bookrunning managers for the offering.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics’ Strong Market Performance and Strategic Initiatives Drive Buy Rating
- Akebia price target raised to $6 from $4 at Piper Sandler
- Akebia Therapeutics Faces Global Regulatory Challenges Amid Brexit and EU Changes
- Akebia Therapeutics Reports Progress in Vafseo Launch
- Akebia Therapeutics’ Earnings Call Highlights Vafseo Success